Daily Sepsis Research Analysis
Analyzed 15 papers and selected 3 impactful papers.
Summary
Analyzed 15 papers and selected 3 impactful articles.
Selected Articles
1. Peripheral Circulating Exosomes Induce Sepsis-associated Liver Injury by Up-regulating STAT1 to Promote Autophagy and Regulating the SLC7A11-GSH-GPX4 Axis to Promote Ferroptosis.
Using LPS-induced murine sepsis and hepatocyte co-cultures, the study shows that circulating exosomes drive sepsis-associated liver injury by upregulating STAT1, which promotes autophagy and ferroptosis via modulation of the SLC7A11–GSH–GPX4 axis. STAT1 inhibition abrogated, while overexpression amplified, exosome-induced inflammatory and cell death pathways, establishing a mechanistic target for SALI.
Impact: Identifies a previously unrecognized STAT1-centered pathway linking exosome signaling to autophagy and ferroptosis in sepsis-associated liver injury, opening avenues for targeted interventions.
Clinical Implications: Suggests therapeutic strategies targeting STAT1 signaling or ferroptosis (e.g., STAT1 inhibitors, ferroptosis blockers) and positions exosome-derived or ferroptosis-related markers as candidates for monitoring SALI.
Key Findings
- Circulating exosomes from septic mice induced inflammatory responses and hepatocyte injury via STAT1-mediated autophagy and ferroptosis.
- STAT1 inhibition abolished, and STAT1 overexpression potentiated, exosome-induced autophagy, ferroptosis, and inflammation.
- In vivo, septic exosomes triggered liver injury; suppressing STAT1 negated effects on the SLC7A11–GSH–GPX4 axis and hepatic inflammation.
Methodological Strengths
- Integrated in vivo and in vitro models with RNA-seq to identify and validate mechanistic drivers.
- Used both loss-of-function and gain-of-function approaches to causally implicate STAT1.
Limitations
- Relies on an LPS-induced sepsis model, which may not recapitulate all facets of human sepsis.
- Exosomal cargo that activates STAT1 was not fully characterized, limiting translational specificity.
Future Directions: Validate STAT1–ferroptosis signatures in human sepsis cohorts; define exosomal cargo; test STAT1/ferroptosis inhibitors in preclinical sepsis; develop exosome-based biomarkers for SALI.
Peripheral exosomes have been implicated in the pathogenesis of multiple organ dysfunction during sepsis. However, their role in sepsis-associated liver injury (SALI) remains unclear. This study aimed to investigate the effects of circulating exosomes on hepatic injury and to elucidate the underlying molecular mechanisms of SALI. A murine sepsis model was established via intraperitoneal injection of lipopolysaccharide (LPS). Peripheral exosomes were isolated and co-cultured with murine hepatocytes (AML12 cells). RNA sequencing identified Signal transducer and activator of transcription 1 (STAT1) as a key regulator in exosome-induced liver injury. Since STAT1 functions upstream of the ferroptosis-related solute carrier family 7 member 11 (SLC7A11)-glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis, further in vivo and in vitro experiments were conducted to clarify its mechanistic role. In vitro, exosomes derived from septic mice enhanced inflammatory responses in AML12 cells via STAT1-mediated autophagy and modulation of the SLC7A11-GSH-GPX4 axis, leading to ferroptosis. Inhibition of STAT1 abrogated these effects, whereas STAT1 overexpression potentiated them. In vivo, septic exosomes (sep-Exo) induced liver injury in mice, while suppression of STAT1 abolished the regulatory effects of sep-Exo on ferroptosis, autophagy, and hepatic inflammation. Our findings reveal a novel mechanism underlying SALI, whereby peripheral exosomes upregulate STAT1 to induce autophagy and modulate the SLC7A11-GSH-GPX4 axis, thereby promoting ferroptosis and hepatic inflammation during sepsis.
2. Comparison of serial pancreatic stone protein, C-reactive protein and procalcitonin for the diagnosis of infection and sepsis in critically Ill patients: a multicentre prospective study.
In a 3-centre prospective ICU cohort (n=272), CRP and procalcitonin showed fair discrimination for infection, with serial procalcitonin improving performance, while PSP trended higher in culture-positive cases. None of the biomarkers (CRP, procalcitonin, PSP) discriminated sepsis at admission, and combinations increased specificity at the cost of accuracy.
Impact: Provides pragmatic, multicentre prospective evidence that routine biomarkers fail to classify sepsis at ICU admission, shaping diagnostic pathways towards serial and multimodal assessment.
Clinical Implications: Avoid relying on single biomarker thresholds to diagnose sepsis at ICU admission; use serial procalcitonin to support infection assessment and integrate clinical criteria, cultures, and organ dysfunction scoring.
Key Findings
- CRP (AUROC 0.77) and procalcitonin (AUROC 0.75) showed fair discrimination for infection at admission.
- Serial measurement improved biomarker performance, especially for procalcitonin (p=0.04 over 24–48 h).
- None of CRP, procalcitonin, or PSP could discriminate sepsis at admission (AUROCs ≈0.54–0.58).
- PSP trended higher in culture-positive infections (median 229 vs. 142 ng/mL; p=0.05), and combining biomarkers increased specificity (93.85%) but reduced accuracy.
Methodological Strengths
- Prospective multicentre design with serial biomarker assessments.
- Clear clinical grouping (infection vs non-infection; sepsis vs non-sepsis) and culture-stratified analyses.
Limitations
- Moderate sample size from three hospitals in a single country may limit generalizability.
- Limited time window (24–48 h) and potential residual confounding in sepsis adjudication.
Future Directions: Validate dynamic, multimarker algorithms with host-response signatures and integrate with clinical scores; assess prognostic utility and antimicrobial stewardship impact.
BACKGROUND: The serial performance of C-reactive protein (CRP), procalcitonin, and emerging biomarker pancreatic stone protein (PSP) was evaluated for the diagnosis of infection and sepsis in patients admitted to the intensive care unit (ICU). METHODS: All consecutive adult patients with suspected infection or sepsis upon their admission to the ICUs of three multi-speciality hospitals in the UAE were enrolled. CRP, procalcitonin, and PSP levels were measured at admission and repeated within 24-48 h. Patients were categorized into infection vs. non-infection, sepsis vs. non-sepsis groups, and into culture-positive and culture-negative subgroups. RESULTS: A total of 272 ICU patients were analyzed. All biomarkers could be used to distinguish infection with CRP (AUROC 0.77; 95% confidence intervals [CI] 0.70-0.83) and procalcitonin (AUROC 0.75; 95% CI 0.68-0.81) showing fair performance. Moreover, serial monitoring at 24-48 h improved performance, especially for procalcitonin (p = 0.04). Among patients with infection, PSP levels were higher in culture-positive compared to culture-negative patients, but the difference did not reach statistical significance (median 229 vs. 142 ng/ml, p = 0.05). However, all three biomarkers failed to discriminate sepsis with an AUROC of 0.56 (95% CI 0.49-0.64) for CRP, 0.54 (95% CI 0.46-0.62) for procalcitonin, and 0.58 (95% CI 0.50-0.66) for PSP, respectively. Combining biomarkers improved specificity (93.85%) but with reduced accuracy. CONCLUSION: Despite a significant rise in all biomarkers, procalcitonin has overall better performance for diagnosing infections. None of the biomarkers could differentiate sepsis at admission.
3. Neutrophil Extracellular Traps as Mediators of Acute Lung Injury: Bridging Clinical and Preclinical Evidence.
This systematic review and meta-analysis demonstrates consistent upregulation of NET-associated components (e.g., MPO-DNA complexes, cfDNA, citH3) in preclinical ALI models and validates elevated NET markers in patients with ALI/ARDS. Findings support NETs as mechanistic drivers and candidate diagnostic biomarkers in sepsis-related lung injury.
Impact: Bridges preclinical and clinical evidence to nominate specific NET-derived markers as diagnostic candidates and mechanistic readouts in ALI/ARDS, informing future biomarker and therapeutic trials.
Clinical Implications: NET-associated biomarkers (e.g., MPO-DNA, cfDNA, citH3) warrant prospective validation for diagnosis/prognosis in ALI/ARDS and may guide patient selection for NET-targeted therapies.
Key Findings
- Preclinical ALI models show significant upregulation of NET components including MPO, MPO-DNA complexes, citH3, cfDNA/dsDNA, and PAD4.
- Clinical studies validate elevated NETs, cfDNA/dsDNA, and MPO-DNA complexes in patients with ALI/ARDS.
- NET-associated biomarkers emerge as mechanistic indicators and potential diagnostic targets in sepsis-related lung injury.
Methodological Strengths
- Systematic search with predefined criteria and random-effects meta-analysis.
- Cross-validation of biomarkers across preclinical and clinical datasets.
Limitations
- Potential heterogeneity across included studies and assays with limited reporting of PRISMA compliance.
- Diagnostic thresholds and clinical utility metrics were not uniformly established.
Future Directions: Prospective studies to define clinically useful cutoffs, longitudinal performance, and to test NET-targeted interventions in ALI/ARDS, especially in septic cohorts.
BACKGROUND: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are multifaceted clinical conditions characterized by uncontrolled inflammatory responses and compromised integrity of the alveolar-capillary barrier. The lack of specific diagnostic tests and effective pharmacologic therapies for ARDS reflects its underlying biological heterogeneity. In sepsis, the excessive formation of neutrophil extracellular traps (NETs) contributes to ALI pathogenesis by inducing endothelial injury, increasing vascular permeability, and amplifying pulmonary inflammation. This meta-analysis integrates findings from clinical and preclinical studies to elucidate disease pathogenesis and inform diagnostic strategies. METHODS: A systematic search of PubMed, Google Scholar, and the Cochrane Library was conducted following predefined inclusion and exclusion criteria. The primary outcome measure was the standardized mean difference with a 95% confidence interval, assessed using a random-effects model. RESULTS: We identified a significant upregulation of NETs and their related components, including myeloperoxidase (MPO), the MPO-DNA complex, neutrophils, citrullinated histone H3 (citH3), cell-free DNA (cfDNA), double-stranded DNA (dsDNA), and peptidylarginine deiminase 4 (PAD4) in preclinical models. Furthermore, we validated the elevated expression of NETs, cfDNA, dsDNA, and the MPO-DNA complex in patients with ALI/ARDS. CONCLUSION: This meta-analysis identified key NET-associated biomarkers that are dysregulated in both patients with ALI and experimental models. These biomarkers are involved in disease pathophysiology and have the potential to serve as diagnostic indicators. These outcomes contribute to a deeper understanding of NET-mediated mechanisms in ALI and support the need for further research on NET-targeted diagnostic approaches and therapeutic strategies.